Cerebras Systems Shares Tumble After Record-Breaking AI Chip IPO
Cerebras Systems stock fell 10% after opening at nearly double its $185 IPO price, raising questions about AI chip valuations despite strong customer contracts.
352 articles
Stay up to date with the latest stock market news, analysis, and market-moving events.
Cerebras Systems stock fell 10% after opening at nearly double its $185 IPO price, raising questions about AI chip valuations despite strong customer contracts.
Nebius Group raises 2026 capex guidance to $25 billion as AI infrastructure demand surges, with Q1 revenue jumping 684% year-over-year amid supply shortages
Semiconductor stocks drive S&P 500 to records, now representing 18% of the index in a two-decade high that raises concerns about market concentration and volatility risks.
Quantum Computing Inc. shares jumped 14.4% after reporting Q1 2026 revenue of $3.7M, up 9,364% year-over-year, driven by strategic acquisitions and a $16M order backlog.
Jefferies analysis reveals AI stocks drive 80% of S&P 500 gains in 2026, supported by 38.5% earnings growth and attractive valuations despite geopolitical concerns.
SpaceX shareholders approve 5-for-1 stock split, adjusting share price to $105.32 ahead of planned $75 billion IPO targeting June 12 launch on Nasdaq exchange.
Wall Street's AI-driven rally encounters headwinds as inflation accelerates to 3.8% and new Fed Chair Kevin Warsh prepares to tackle mounting economic pressures.
Realty Income Corporation has delivered 31 consecutive years of dividend increases with a 5.1% yield, making it a compelling study for income investors.
Property & casualty insurers show mixed Q1 2026 results, with Travelers missing estimates while Stewart Information Services leads sector performance.
KinderCare Learning stock dropped 8% Friday despite beating Q1 estimates, as investors focused on declining enrollment in the company's core early childhood education centers.
Exelixis faces patent cliff for flagship drug Cabometyx by 2030 while advancing promising pipeline candidate zanzalintinib through clinical trials across multiple cancer indications.
Genpact stock fell 7.5% despite beating Q1 revenue and earnings expectations, as weak Q2 guidance overshadowed positive results and raised concerns about near-term growth.
Get the latest stock market news and analysis delivered to your inbox.
No spam, unsubscribe anytime. See our Privacy Policy.
We use cookies to enhance your browsing experience and analyze site traffic. By clicking "Accept", you consent to our use of cookies.